Home  »  Companies   »  Gossamer Bio Inc. (NASDAQ: GOSS) Stock Price Forec...

Gossamer Bio Inc. (NASDAQ: GOSS) Stock Price Forecast: $100

Gossamer Bio Inc. (NASDAQ:GOSS) shares, rose in value on Thursday, 08/04/22, with the stock price up by 4.90% to the previous day’s close as strong demand from buyers drove the stock to $12.85.

Actively observing the price movement in the last trading, the stock closed the session at $12.25, falling within a range of $12.225 and $12.99. The value of beta (5-year monthly) was 0.85. Referring to stock’s 52-week performance, its high was $14.30, and the low was $5.64. On the whole, GOSS has fluctuated by 59.23% over the past month.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .

Sponsored

With the market capitalization of Gossamer Bio Inc. currently standing at about $1.05 billion, investors are eagerly awaiting this quarter’s results, scheduled for Feb 23, 2022 – Feb 28, 2022. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be -$0.7, which is expected to increase to -$0.39 for fiscal year -$2.73 and then to about -$2.41 by fiscal year 2023. Data indicates that the EPS growth is expected to be 12.80% in 2023, while the next year’s EPS growth is forecast to be 11.70%.

Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that GOSS’s technical picture suggests that short-term indicators denote the stock is a 100% Buy on average. However, medium term indicators have put the stock in the category of Hold while long term indicators on average have been pointing out that it is a 50% Buy.

9 analyst(s) have assigned their ratings of the stock’s forecast evaluation on a scale of 1.00-5.00 to indicate a strong buy to a strong sell recommendation. The stock is rated as a Hold by 0 analyst(s), 7 recommend it as a Buy and 2 called the GOSS stock Overweight. In the meantime, 0 analyst(s) believe the stock as Underweight and 0 think it is a Sell. Thus, investors eager to increase their holdings of the company’s stock will have an opportunity to do so as the average rating for the stock is Buy.

The stock’s technical analysis shows that the PEG ratio is about 0, with the price of GOSS currently trading nearly 19.99% and 48.68% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 73.68, while the 7-day volatility ratio is showing 5.41% which for the 30-day chart, stands at 8.05%. Furthermore, Gossamer Bio Inc. (GOSS)’s beta value is 1.05, and its average true range (ATR) is 0.73. The company’s stock has been forecasted to trade at an average price of $15.78 over the course of the next 52 weeks, with a low of $12.00 and a high of $21.00. Based on these price targets, the low is 6.61% off current price, whereas the price has to move -63.42% to reach the yearly target high. Additionally, analysts’ median price of $15.00 is likely to be welcomed by investors because it represents a decrease of -16.73% from the current levels.

A comparison of Gossamer Bio Inc. (GOSS) with its peers suggests the former has fared considerably weaker in the market. GOSS showed an intraday change of 4.90% in last session, and over the past year, it grew by 62.86%%. In comparison, Johnson & Johnson (JNJ) has moved lower at -1.60% on the day and was down -0.91% over the past 12 months. On the other hand, the price of Pfizer Inc. (PFE) has fallen 0.00% on the day. The stock, however, is off 10.33% from where it was a year ago. Additionally, there is a loss of -1.61% for AbbVie Inc. (ABBV) in last trading while the stock has seen an overall depriciation of 20.72%% over the past year. Other than that, the overall performance of the S&P 500 during the last trading session shows that it lost -0.08%. Meanwhile, the Dow Jones Industrial Slipped by -0.26%.

Data on historical trading for Gossamer Bio Inc. (NASDAQ:GOSS) indicates that the trading volumes over the past 10 days have averaged 1.02 million and over the past 3 months, they’ve averaged 1.31 million. According to company’s latest data on outstanding shares, there are 75.89 million shares outstanding.

Nearly 1.50% of Gossamer Bio Inc.’s shares belong to company insiders and institutional investors own 89.90% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 13.51 million shares as on Jul 14, 2022, resulting in a short ratio of 6.94. According to the data, the short interest in Gossamer Bio Inc. (GOSS) stood at 17.52% of shares outstanding as of Jul 14, 2022; the number of short shares registered in Jun 14, 2022 reached 12.09 million. The stock has risen by 13.62% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the GOSS stock heading into the next quarter.

Leave a Comment

Your email address will not be published.

[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]